[go: up one dir, main page]

CL2017000944A1 - Compuesto heterocíclico - Google Patents

Compuesto heterocíclico

Info

Publication number
CL2017000944A1
CL2017000944A1 CL2017000944A CL2017000944A CL2017000944A1 CL 2017000944 A1 CL2017000944 A1 CL 2017000944A1 CL 2017000944 A CL2017000944 A CL 2017000944A CL 2017000944 A CL2017000944 A CL 2017000944A CL 2017000944 A1 CL2017000944 A1 CL 2017000944A1
Authority
CL
Chile
Prior art keywords
rbp4
heterocyclic compound
retinol
disease
prevention
Prior art date
Application number
CL2017000944A
Other languages
English (en)
Inventor
Yoshihiro Banno
Masahiro Kamaura
Kazuaki Takami
Koichiro Fukuda
Shigekazu Sasaki
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2017000944A1 publication Critical patent/CL2017000944A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/46—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/36—One oxygen atom
    • C07D263/38—One oxygen atom attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

<p>SE PROPORCIONA UN COMPUESTO HETEROCÍCLICO QUE TIENE UNA ACCIÓN SUPERIOR DE REDUCCIÓN DE RBP4 Y DE UTILIDAD COMO UN MEDICAMENTO PARA LA PREVENCIÓN O EL TRATAMIENTO DE UNA ENFERMEDAD O UN SÍNTOMA MEDIADOS POR UN INCREMENTO EN RBP4 O RETINOL PROPORCIONADO POR RBP4. UN COMPUESTO REPRESENTADO POR LA FÓRMULA (I), EN DONDE CADA SÍMBOLO ES COMO SE DEFINE EN LA DESCRIPCIÓN O UNA SAL DEL MISMO TIENE UNA ACCIÓN SUPERIOR DE REDUCCIÓN DE RBP4 Y ES DE UTILIDAD COMO UN MEDICAMENTO PARA LA PREVENCIÓN O EL TRATAMIENTO DE UNA ENFERMEDAD O SÍNTOMA MEDIDOS POR UN INCREMENTO EN RBP4 O RETINOL PROPORCIONADO POR RBP4.</p>
CL2017000944A 2014-10-24 2017-04-17 Compuesto heterocíclico CL2017000944A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014217770 2014-10-24

Publications (1)

Publication Number Publication Date
CL2017000944A1 true CL2017000944A1 (es) 2018-01-12

Family

ID=55760964

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000944A CL2017000944A1 (es) 2014-10-24 2017-04-17 Compuesto heterocíclico

Country Status (38)

Country Link
US (4) US10214498B2 (es)
EP (2) EP3848353A1 (es)
JP (2) JP6588027B2 (es)
KR (1) KR102490156B1 (es)
CN (2) CN107108506B (es)
AR (1) AR104342A1 (es)
AU (2) AU2015336480B2 (es)
BR (1) BR112017007138A2 (es)
CA (1) CA2965465C (es)
CL (1) CL2017000944A1 (es)
CO (1) CO2017003699A2 (es)
CR (1) CR20170160A (es)
CY (1) CY1123842T1 (es)
DK (1) DK3210973T3 (es)
DO (1) DOP2017000098A (es)
EA (1) EA033446B1 (es)
EC (1) ECSP17026687A (es)
ES (1) ES2848999T3 (es)
HR (1) HRP20210320T1 (es)
HU (1) HUE053443T2 (es)
IL (2) IL285105B2 (es)
LT (1) LT3210973T (es)
MA (2) MA39688B1 (es)
MX (2) MX2017004629A (es)
MY (1) MY183209A (es)
PE (1) PE20170669A1 (es)
PH (1) PH12017500747B1 (es)
PL (1) PL3210973T3 (es)
PT (1) PT3210973T (es)
RS (1) RS61504B1 (es)
SG (1) SG11201702312UA (es)
SI (1) SI3210973T1 (es)
SM (1) SMT202100082T1 (es)
TN (1) TN2017000097A1 (es)
TW (2) TWI749661B (es)
UA (1) UA121871C2 (es)
WO (1) WO2016063933A1 (es)
ZA (1) ZA201703344B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA121871C2 (uk) * 2014-10-24 2020-08-10 Такеда Фармасьютікал Компані Лімітед Гетероциклічна сполука
SG11201908691PA (en) 2017-03-20 2019-10-30 Broad Inst Inc Compounds and methods for the treatment of parasitic diseases
TWI841532B (zh) * 2017-06-15 2024-05-11 開曼群島商貝利特生物股份有限公司 以稠合雙環吡唑治療代謝疾病之方法
EP3638239A4 (en) * 2017-06-15 2021-03-10 Belite Bio, Inc METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH RBP4 USING TRIAZOLOPYRIDINES
WO2020028723A1 (en) * 2018-08-01 2020-02-06 The Trustees Of Columbia University In The City Of New York Rbp4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout
CN111690695A (zh) * 2020-05-19 2020-09-22 浙江工业大学 3-苯氨基丙羟肟酸的酶促微流控在线合成方法
CN111690698A (zh) * 2020-05-19 2020-09-22 浙江工业大学 两步串联流动合成3-（苯并[d][1,3]二氧-5-氨基）丙羟肟酸的方法
WO2022256301A1 (en) * 2021-06-01 2022-12-08 Stargazer Pharmaceuticals, Inc. Methods and compounds for treating subjects with stargardt disease
CN116286900B (zh) * 2022-10-28 2024-04-26 昆明理工大学 一种乙酸渗透酶A基因RkAcpa及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3625970A (en) 1968-04-17 1971-12-07 Cutter Lab 1-(disubstituted phenyl or benzyl)-1h-indazol-3-yloxyacetic acid
US5239080A (en) 1989-02-08 1993-08-24 Takeda Chemical Industries, Ltd. Oxazole compounds and their use as antidiabetic and bone-reduction inhibitory agents
EP0440183A1 (en) 1990-02-01 1991-08-07 Takeda Chemical Industries, Ltd. Oxazole compounds, their production and use
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
WO1999022735A1 (en) 1997-10-30 1999-05-14 Merck & Co., Inc. Somatostatin agonists
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
WO2001025228A1 (fr) 1999-10-07 2001-04-12 Tadeka Chemical Industries, Ltd. Derives d'amines
CZ20021604A3 (cs) 1999-11-10 2002-09-11 Takeda Chemical Industries, Ltd. Pětičlenné N-heterocyklické sloučeniny, farmaceutický přípravek a činidlo je obsahující a jejich použití
GB0020351D0 (en) 2000-08-17 2000-10-04 Catalyst Biomedica Ltd Treatment of hyperproliferative diseases
DE10149568A1 (de) 2001-10-08 2003-04-24 Consequence Gmbh Verfahren zur Sequenzanalyse von Polypeptiden
US20050245571A1 (en) 2001-10-19 2005-11-03 Hidenori Abe Amine derivative
US20040214788A1 (en) 2003-03-11 2004-10-28 Raj Madhwa H.G. Treatment of prostate cancer
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
JP4767850B2 (ja) 2003-08-20 2011-09-07 エミスフィアー テクノロジーズ インコーポレイテッド グルカゴン様ペプチド（ｇｌｐ）−１化合物またはメラノコルチン４受容体（ｍｃ４）アゴニストペプチドの経口デリバリーのための化合物、方法および製剤
US7553631B2 (en) 2003-12-11 2009-06-30 Beth Israel Deaconess Medical Center, Inc. RBP4 in insulin sensitivity/resistance, diabetes, and obesity
WO2005120583A2 (en) 2004-06-14 2005-12-22 Wisconsin Alumni Research Foundation Method for preventing or treating cardiac hypertrophy
WO2006007314A1 (en) 2004-06-23 2006-01-19 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivatives
US20080033053A1 (en) 2004-07-22 2008-02-07 Wolfgang Curt D Cross-Reference To Related Applications
WO2006042252A2 (en) 2004-10-08 2006-04-20 Potentia Pharmeceuticals, Inc. Viral complement control proteins for eye disorders
KR20090029814A (ko) 2006-06-22 2009-03-23 시리온 테라퓨틱스, 인크. 메갈린 활성의 조절을 통한 안질환의 치료 방법 및 조성물
EP2170306A1 (en) 2007-06-26 2010-04-07 Lexicon Pharmaceuticals, Inc. Methods of treating serotonin-mediated diseases and disorders
EP2170335A1 (en) 2007-06-26 2010-04-07 Lexicon Pharmaceuticals, Inc. Compositions comprising tryptophan hydroxylase inhibitors
EP2205234A4 (en) 2007-09-27 2010-12-22 Revision Therapeutics Inc METHODS AND COMPOUNDS FOR THE TREATMENT OF RETINOL RELATED DISEASES
US7973079B2 (en) 2007-09-27 2011-07-05 Revision Therapeutics, Inc. Methods and compounds for treating retinol-related diseases
US8586571B2 (en) 2007-10-18 2013-11-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2009143390A2 (en) 2008-05-22 2009-11-26 Isis Pharmaceuticals, Inc. Methods for modulating expression of rbp4
CA2725680A1 (en) * 2008-05-30 2009-12-03 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP2012523461A (ja) * 2009-04-13 2012-10-04 アイアールエム・リミテッド・ライアビリティ・カンパニー レチノール結合タンパク質４（ｒｂｐ４）へのレチノールの結合を調節するための組成物および方法
AU2010237750A1 (en) * 2009-04-16 2011-11-17 Takeda Pharmaceutical Company Limited Derivatives of N-acyl-N'-phenylpiperazine useful (inter alia) for the prophylaxis or treatment of diabetes
WO2011059776A2 (en) 2009-10-28 2011-05-19 Revision Therapeutics, Inc Prophylaxis of skin cancer with retinamides
EP2521724B1 (en) 2009-12-11 2016-11-23 Nono Inc. Agents and methods for treating ischemic and other diseases
KR20130053404A (ko) 2010-03-30 2013-05-23 베르선 코포레이션 트롬빈 억제제로서의 다중치환된 방향족 화합물
WO2012071369A2 (en) 2010-11-24 2012-05-31 The Trustees Of Columbia University In The City Of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
LT2707101T (lt) 2011-05-12 2019-05-27 Proteostasis Therapeutics, Inc. Proteostazę reguliuojantys agentai
GB201205679D0 (en) 2012-03-30 2012-05-16 Dyson Technology Ltd A hand held appliance
WO2013166041A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Transthyretin ligands capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular
US9580400B2 (en) 2013-02-26 2017-02-28 Northeastern University Cannabinergic nitrate esters and related analogs
WO2014160409A1 (en) 2013-03-14 2014-10-02 The Trustees Of Columbia University In The City Of New York Rbp4 antagonists for the treatment of age-related macular degeneration and stargardt disease
WO2014153643A1 (en) 2013-03-26 2014-10-02 The University Of British Columbia Compositions and methods for use thereof in the treatment of aniridia
CN106458856A (zh) 2014-03-07 2017-02-22 约翰霍普金斯大学 组蛋白赖氨酸特异性的脱甲基酶(lsd1)和组蛋白脱乙酰基酶(hdac)的抑制剂
EA034931B1 (ru) 2014-10-24 2020-04-08 Бристол-Майерс Сквибб Компани Индолкарбоксамидные соединения
UA121871C2 (uk) 2014-10-24 2020-08-10 Такеда Фармасьютікал Компані Лімітед Гетероциклічна сполука
MX374724B (es) 2014-10-24 2025-03-06 Bristol Myers Squibb Company Derivados de carbazol.
WO2016172631A2 (en) 2015-04-24 2016-10-27 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
US10189797B2 (en) 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use

Also Published As

Publication number Publication date
UA121871C2 (uk) 2020-08-10
IL251695B (en) 2021-08-31
SMT202100082T1 (it) 2021-03-15
TW201714876A (zh) 2017-05-01
AR104342A1 (es) 2017-07-12
PE20170669A1 (es) 2017-06-06
CA2965465A1 (en) 2016-04-28
HRP20210320T1 (hr) 2021-04-30
MX2021001188A (es) 2021-04-19
LT3210973T (lt) 2021-03-25
IL285105B2 (en) 2023-03-01
US10214498B2 (en) 2019-02-26
KR20170067791A (ko) 2017-06-16
EP3210973B1 (en) 2020-12-02
MA53568A (fr) 2022-02-23
CO2017003699A2 (es) 2017-07-28
IL285105A (en) 2021-08-31
CR20170160A (es) 2017-06-15
EP3210973A1 (en) 2017-08-30
JPWO2016063933A1 (ja) 2017-08-03
PH12017500747A1 (en) 2017-10-30
PT3210973T (pt) 2021-02-12
DK3210973T3 (da) 2021-02-08
ECSP17026687A (es) 2017-09-29
CN107108506A (zh) 2017-08-29
US10975043B2 (en) 2021-04-13
AU2015336480B2 (en) 2020-04-02
JP2020007347A (ja) 2020-01-16
CY1123842T1 (el) 2022-05-27
BR112017007138A2 (pt) 2017-12-26
EA033446B1 (ru) 2019-10-31
JP6588027B2 (ja) 2019-10-09
ES2848999T3 (es) 2021-08-13
IL251695A0 (en) 2017-06-29
TWI749661B (zh) 2021-12-11
MX2017004629A (es) 2017-06-30
KR102490156B1 (ko) 2023-01-18
TWI703131B (zh) 2020-09-01
AU2015336480A2 (en) 2017-06-01
AU2015336480A1 (en) 2017-05-25
SI3210973T1 (sl) 2021-04-30
US20190119225A1 (en) 2019-04-25
PH12017500747B1 (en) 2017-10-30
RS61504B1 (sr) 2021-03-31
CN107108506B (zh) 2022-06-21
JP6995094B2 (ja) 2022-02-21
EA201790912A1 (ru) 2017-09-29
US10544111B2 (en) 2020-01-28
EP3848353A1 (en) 2021-07-14
AU2020204426A1 (en) 2020-07-23
MA39688A (fr) 2017-08-30
IL285105B (en) 2022-11-01
DOP2017000098A (es) 2017-07-15
HUE053443T2 (hu) 2021-06-28
US20180237404A1 (en) 2018-08-23
PL3210973T3 (pl) 2021-06-28
AU2020204426B2 (en) 2022-02-03
CA2965465C (en) 2023-08-01
US20210340114A1 (en) 2021-11-04
WO2016063933A1 (ja) 2016-04-28
EP3210973A4 (en) 2018-04-25
TW202042805A (zh) 2020-12-01
MY183209A (en) 2021-02-18
CN115197160A (zh) 2022-10-18
TN2017000097A1 (en) 2018-07-04
US20200157062A1 (en) 2020-05-21
MA39688B1 (fr) 2021-02-26
ZA201703344B (en) 2018-08-29
SG11201702312UA (en) 2017-05-30

Similar Documents

Publication Publication Date Title
CL2017000944A1 (es) Compuesto heterocíclico
CY1118168T1 (el) Διπλα ειδικα αντισωματα εναντι cd3εψιλον και bcma
CL2016002971A1 (es) Combinación.
UY35821A (es) Compuesto heterocíclico
CR20160367A (es) Compuesto heterocíclico fusionado
GT201600185A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
CR20150495A (es) Procesos para la preparación de un agente inductor de la apoptosis
MX374007B (es) Uso del cannabidiol en el tratamiento del complejo de esclerosis tuberosa.
ECSP16067163A (es) Compuesto heterocíclico
MX2020012132A (es) Compuestos de azapiridona y usos de los mismos.
CO7141410A2 (es) Compuesto heterocíclico nitrogenado
MX2018009459A (es) Derivado de sulfonamida y composicion farmaceutica que contiene el mismo.
MX380252B (es) Crenezumab para usarse en el tratamiento de enfermedad de alzheimer.
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
FR3023731B1 (fr) Procede de synthese de nanocomposites a base de tio2 et de nanostructures carbonees.
UY35650A (es) Compuesto heterocíclico
BR112016015578A2 (pt) Inibidores de 17beta-hidroxiesteroide desidrogenases tipo 1 e tipo 2
EA201691036A1 (ru) Новое соединение для лечения тяжелой гипогликемии
FR3017550B1 (fr) Machine de traitement de dechets infectieux, notamment medicaux
DOP2015000290A (es) Benzoxazoles sustituidos
SI3148588T1 (sl) N,N-bis-2-merkaptoetil izoftalamid za zdravljenje Parkinsonove bolezni
TH1601002013A (th) ผลิตภัณฑ์สวมใส่เเบบกางเกงชั้นในชนิดใช้เเล้วทิ้ง
TH1501000987A (th) ซัลฟาโมอิล แอริลเอไมด์และการใช้ของสิ่งนั้นเป็นยาสำหรับการบำบัดตับอักเสบ b
AR104570A1 (es) Métodos de tratamiento de una enfermedad neurodegenerativa